Glu275 and Lys268 have also been shown to contribute to the active site, indicating there are four active sites, each of which is formed from regions of three subunits. ADSL deficiency in different people is often caused by different mutations to the enzyme, more than 50 different mutations in the ADSL gene have been discovered

Diagnosis
In terms of the diagnosis of adenylosuccinate lyase deficiency one should look for (or exam/method):
MRI
Demonstration of succinylpurines in extracellular fluids like plasma, cerebrospinal fluid and/or urine using high-pressure liquid chromatography, with or without mass spectroscopy
Genetic testing - genomic cDNA sequencing of the ADSL gene and characterization of mutant proteins. Treatment
Treatment of adenylosuccinate lyase deficiency can be done via epilepsy management with anticonvulsive drugs. Additionally the following options include:

D-ribose and uridine administration
Ketogenic diet
S-adenosyl-l-methionine

Prognosis
The prognosis of this condition in childhood usually has a stable outcome, whereas in neonatal is almost always fatal, according to Jurecka, et al. See also
Adenylosuccinate
Adenylosuccinate lyase
List of genetic disorders

References
Further reading
Saudubray, Jean-Marie; Berghe, Georges van den; Walter, John H. (2011-11-16). Inborn Metabolic Diseases: Diagnosis and Treatment. Springer Science & Business Media. ISBN 9783642157202. Blau, Nenad; Hoffmann, Georg F.; Leonard, J. V.; Clarke, Joe T. R. (2006-01-16). Physicians Guide to the Treatment and Follow-Up of Metabolic Diseases. Springer Science & Business Media. ISBN 9783540289623. == External links ==
Encephalocraniocutaneous lipomatosis (ECCL), is a rare condition primarily affecting the brain, eyes, and skin of the head and face. It is characterized by unilateral subcutaneous and intracranial lipomas, alopecia, unilateral porencephalic cysts, epibulbar choristoma and other ophthalmic abnormalities. It was named after Haberland and Perou who first described it. Signs and Symptoms
Eighty to ninety percent of those with encephalocraniocutaneous lipomatosis are  unable to produce and keep fat tissue and have multiple lipomas. Other types of growths, including jaw tumours, may also occur.Approximately two thirds of individuals with Encephalocraniocutaneous lipomatosis have intracranial and/or intraspinal lipomas. They also have an increased risk of developing a form of brain cancer known as a glioma. Other neurological issues that can occur include seizures, spasticity and variable intellectual disability. However, approximately one third of effected individuals have typical intelligence.The most common ocular abnormality in encephalocraniocutaneous lipomatosis is a form of benign growth called a choristoma which can occur in one or both eyes. These may effect vision. Other ocular symptoms include  abnormally small eyes, small pupils, iris hypoplasia, sclerocornea, hypertrophic conjunctivae, an absent macular reflex and anterior chamber anomalies. There may be eyelid colobomas and short or abnormal palpebral fissures. Skin tags often grow around the eyelids. Cause
History
This condition was first described in 1970. See also
Nevus psiloliparus

References


== External links ==